Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
Cancer Genetics and Cytogenetics|May 18, 2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implicationsAlfonso Zaccaria, Nicoletta Testoni, Anna Maria Valenti, et al.
Blood|March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Frontiers in Oncology|June 14, 2021
Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian SubstudyLidia Borghi, Gianantonio Rosti, Alessandro Maggi, et al.
Acta Oncologica (Stockholm, Sweden)|September 9, 2021
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational studyFabio Stagno, Massimo Breccia, Mario Annunziata, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Frontiers in Oncology|March 21, 2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML StudyAlessandra Iurlo, Daniele Cattaneo, Silvia Artuso, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
Leukemia & Lymphoma|November 6, 2020
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemiaFabio Efficace, Alessandra Iurlo, Andrea Patriarca, et al.
The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
Cancer Genetics and Cytogenetics|May 18, 2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implicationsAlfonso Zaccaria, Nicoletta Testoni, Anna Maria Valenti, et al.
Blood|March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Frontiers in Oncology|June 14, 2021
Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian SubstudyLidia Borghi, Gianantonio Rosti, Alessandro Maggi, et al.
Acta Oncologica (Stockholm, Sweden)|September 9, 2021
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational studyFabio Stagno, Massimo Breccia, Mario Annunziata, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Frontiers in Oncology|March 21, 2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML StudyAlessandra Iurlo, Daniele Cattaneo, Silvia Artuso, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
Leukemia & Lymphoma|November 6, 2020
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemiaFabio Efficace, Alessandra Iurlo, Andrea Patriarca, et al.
The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Pageof 16